Publications 2021

Arnesen KE, Phung AV, Randsborg K, Mork I, Thorvall M, Langslet G, Svilaas A, Wium C, Ose L, Retterstøl K (2021)
Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study
Front Pharmacol, 11, 560958
DOI 10.3389/fphar.2020.560958, PubMed 33737874

Publications 2020

Representatives of the Global Familial Hypercholesterolemia Community, Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, Almahmeed W, Alonso R, Al-Rasadi K, Badimon L, Bernal LM, Bogsrud MP, Braun LT, Brunham L, Catapano AL, Cillíková K, Corral P, Cuevas R, Defesche JC, Descamps OS, de Ferranti S, Eiselé JL, Elikir G, Folco E, Freiberger T et al. (2020)
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action
JAMA Cardiol, 5 (2), 217-229
DOI 10.1001/jamacardio.2019.5173, PubMed 31895433

Publications 2018

Mundal LJ, Igland J, Veierød MB, Holven KB, Ose L, Selmer RM, Wisloff T, Kristiansen IS, Tell GS, Leren TP, Retterstøl K (2018)
Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia
Heart, 104 (19), 1600-1607
DOI 10.1136/heartjnl-2017-312706, PubMed 29622598

Publications 2016

Mundal L, Igland J, Ose L, Holven KB, Veierød MB, Leren TP, Retterstøl K (2016)
Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013
Eur J Prev Cardiol, 24 (2), 137-144
DOI 10.1177/2047487316676135, PubMed 27794106

Mundal L, Veierød MB, Halvorsen T, Holven KB, Ose L, Iversen PO, Tell GS, Leren TP, Retterstøl K (2016)
Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study
Eur J Prev Cardiol, 23 (18), 1962-1969
DOI 10.1177/2047487316666371, PubMed 27558979

Torvik K, Narverud I, Ottestad I, Svilaas A, Gran JM, Retterstøl K, Ellingvåg A, Strøm E, Ose L, Veierød MB, Holven KB (2016)
Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia
Atherosclerosis, 252, 21-27
DOI 10.1016/j.atherosclerosis.2016.07.913, PubMed 27494447

Publications 2015

Langslet G, Bogsrud MP, Halvorsen I, Fjeldstad H, Retterstøl K, Veierød MB, Ose L (2015)
Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood
J Clin Lipidol, 9 (6), 778-785
DOI 10.1016/j.jacl.2015.08.008, PubMed 26687698

Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierød MB, Leren TP, Retterstøl K (2015)
[Increased mortality in familial hypercholesterolemia]
Tidsskr Nor Laegeforen, 135 (11), 1024-5
DOI 10.4045/tidsskr.15.0244, PubMed 26080775

Narverud I, van Lennep JR, Christensen JJ, Versmissen J, Gran JM, Iversen PO, Aukrust P, Halvorsen B, Ueland T, Ulven SM, Ose L, Veierød MB, Sijbrands E, Retterstøl K, Holven KB (2015)
Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia
Atherosclerosis, 243 (1), 155-60
DOI 10.1016/j.atherosclerosis.2015.09.014, PubMed 26386212

Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK et al. (2015)
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
Eur Heart J, 36 (36), 2425-37
DOI 10.1093/eurheartj/ehv157, PubMed 26009596

Publications 2014

Holven KB, Narverud I, Lindvig HW, Halvorsen B, Langslet G, Nenseter MS, Ulven SM, Ose L, Aukrust P, Retterstøl K (2014)
Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment
Atherosclerosis, 233 (2), 561-567
DOI 10.1016/j.atherosclerosis.2014.01.022, PubMed 24530965

Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierød MB, Leren TP, Retterstøl K (2014)
Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010
J Am Heart Assoc, 3 (6), e001236
DOI 10.1161/JAHA.114.001236, PubMed 25468658

Narverud I, Retterstøl K, Iversen PO, Halvorsen B, Ueland T, Ulven SM, Ose L, Aukrust P, Veierød MB, Holven KB (2014)
Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review
Atherosclerosis, 235 (2), 299-309
DOI 10.1016/j.atherosclerosis.2014.05.917, PubMed 24908240

Versmissen J, Oosterveer DM, Yazdanpanah M, Dehghan A, Hólm H, Erdman J, Aulchenko YS, Thorleifsson G, Schunkert H, Huijgen R, Vongpromek R, Uitterlinden AG, Defesche JC, van Duijn CM, Mulder M, Dadd T, Karlsson HD, Ordovas J, Kindt I, Jarman A, Hofman A, van Vark-van der Zee L, Blommesteijn-Touw AC, Kwekkeboom J, Liem AH et al. (2014)
Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach
Eur J Hum Genet, 23 (3), 381-7
DOI 10.1038/ejhg.2014.101, PubMed 24916650

Publications 2013

Bogsrud MP, Langslet G, Ose L, Arnesen KE, Sm Stuen MC, Malt UF, Woldseth B, Retterstøl K (2013)
No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy
Scand Cardiovasc J, 47 (2), 80-7
DOI 10.3109/14017431.2012.756119, PubMed 23301875

Holven KB, Retterstøl K, Ueland T, Ulven SM, Nenseter MS, Sandvik M, Narverud I, Berge KE, Ose L, Aukrust P, Halvorsen B (2013)
Subjects with low plasma HDL cholesterol levels are characterized by an inflammatory and oxidative phenotype
PLoS One, 8 (11), e78241
DOI 10.1371/journal.pone.0078241, PubMed 24244297

Langslet G, Ose L (2013)
Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia
Expert Rev Cardiovasc Ther, 11 (8), 1061-6
DOI 10.1586/14779072.2013.814851, PubMed 23984929

Molven I, Retterstøl K, Andersen LF, Veierød MB, Narverud I, Ose L, Svilaas A, Wandel M, Holven KB (2013)
Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children
J Nutr Sci, 2, e32
DOI 10.1017/jns.2013.27, PubMed 25191582

Nenseter MS, Aukrust P, Ose L, Holven KB (2013)
Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy
Scand J Clin Lab Invest, 74 (1), 1-7
DOI 10.3109/00365513.2013.854926, PubMed 24236948

Ottestad I, Ose L, Wennersberg MH, Granlund L, Kirkhus B, Retterstøl K (2013)
Phytosterol capsules and serum cholesterol in hypercholesterolemia: a randomized controlled trial
Atherosclerosis, 228 (2), 421-5
DOI 10.1016/j.atherosclerosis.2013.03.001, PubMed 23623012

Publications 2012

Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, Brekke M, Retterstøl K, Arnesen KE, Ose L (2012)
Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia
J Clin Lipidol, 6 (4), 331-9
DOI 10.1016/j.jacl.2012.03.004, PubMed 22836070

Narverud I, Halvorsen B, Nenseter MS, Retterstøl K, Yndestad A, Dahl TB, Ulven SM, Olstad OK, Ose L, Holven KB, Aukrust P (2012)
Oxidized LDL level is related to gene expression of tumour necrosis factor super family members in children and young adults with familial hypercholesterolaemia
J Intern Med, 273 (1), 69-78
DOI 10.1111/j.1365-2796.2012.02584.x, PubMed 22891927

Narverud I, Iversen PO, Aukrust P, Halvorsen B, Ueland T, Johansen SG, Nenseter MS, Sandset PM, Ulven SM, Ose L, Retterstøl K, Holven KB (2012)
Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH
Thromb Res, 131 (2), 178-82
DOI 10.1016/j.thromres.2012.11.008, PubMed 23199546

Nenseter MS, Bogsrud MP, Græsdal A, Narverud I, Halvorsen B, Ose L, Aukrust P, Holven KB (2012)
LDL-apheresis affects markers of endothelial function in patients with homozygous familial hypercholesterolemia
Thromb Res, 130 (5), 823-5
DOI 10.1016/j.thromres.2012.06.004, PubMed 22728023

Nenseter MS, Narverud I, Græsdal A, Bogsrud MP, Aukrust P, Retterstøl K, Ose L, Halvorsen B, Holven KB (2012)
Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis
J Clin Lipidol, 7 (2), 109-16
DOI 10.1016/j.jacl.2012.08.001, PubMed 23415429

Nenseter MS, Narverud I, Græsdal A, Bogsrud MP, Halvorsen B, Ose L, Aukrust P, Holven KB (2012)
Elevated serum MMP-9/TIMP-1 ratio in patients with homozygous familial hypercholesterolemia: effects of LDL-apheresis
Cytokine, 61 (1), 194-8
DOI 10.1016/j.cyto.2012.09.016, PubMed 23131422

Publications 2011

Gandelman K, Glue P, Laskey R, Jones J, LaBadie R, Ose L (2011)
An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia
Pediatr Cardiol, 32 (4), 433-41
DOI 10.1007/s00246-011-9885-z, PubMed 21259004

Kusters DM, de Beaufort C, Widhalm K, Guardamagna O, Bratina N, Ose L, Wiegman A (2011)
Paediatric screening for hypercholesterolaemia in Europe
Arch Dis Child, 97 (3), 272-6
DOI 10.1136/archdischild-2011-300081, PubMed 21949015

Nenseter MS, Lindvig HW, Ueland T, Langslet G, Ose L, Holven KB, Retterstøl K (2011)
Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia
Atherosclerosis, 216 (2), 426-32
DOI 10.1016/j.atherosclerosis.2011.02.007, PubMed 21376325

Ose L (2011)
Pitavastatin: finding its place in therapy
Ther Adv Chronic Dis, 2 (2), 101-17
DOI 10.1177/2040622310389227, PubMed 23251745

Svilaas A, Strøm EC, Johansen SG, Vebenstad G, Svilaas T, Ose L (2011)
[Assessment of dietary habits and life style]
Tidsskr Nor Laegeforen, 131 (5), 454
DOI 10.4045/tidsskr.10.0799, PubMed 21383795

Publications 2010

Bogsrud MP, Ose L, Langslet G, Ottestad I, Strøm EC, Hagve TA, Retterstøl K (2010)
HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study
Scand Cardiovasc J, 44 (4), 197-200
DOI 10.3109/14017431003624123, PubMed 20636227

Langslet G, Ottestad I, Retterstøl K, Ose L (2010)
[Clinical trials--viewpoints from participants]
Tidsskr Nor Laegeforen, 130 (16), 1606-8
DOI 10.4045/tidsskr.09.0030, PubMed 20805857

Narverud I, Ueland T, Nenseter MS, Retterstøl K, Telle-Hansen VH, Halvorsen B, Ose L, Aukrust P, Holven KB (2010)
Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor α system and interleukin-10
Atherosclerosis, 214 (1), 163-8
DOI 10.1016/j.atherosclerosis.2010.10.002, PubMed 21040915

Ose L (2010)
Pitavastatin: a distinctive lipid-lowering drug
Clin. Lipidol., 5 (3), 309-323
DOI 10.2217/CLP.10.28

Ose L (2010)
Familiær hyperkolesterolæmi
[S.l.] : Genzyme
BIBSYS 101621493

Ose L, Budinski D, Hounslow N, Arneson V (2010)
Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia (vol 210, pg 202, 2010)
Atherosclerosis, 212 (2), 704
DOI 10.1016/j.atherosclerosis.2010.05.023

Publications 2009

Khoury J, Amundsen AL, Tonstad S, Henriksen T, Ose L, Retterstøl K, Iversen PO (2009)
Evidence for impaired physiological decrease in the uteroplacental vascular resistance in pregnant women with familial hypercholesterolemia
Acta Obstet Gynecol Scand, 88 (2), 222-6
DOI 10.1080/00016340802503047, PubMed 18972234

Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, Davidson MH, Zwinderman AH, Schwocho LR, Stein EA, CAPTIVATE Investigators (2009)
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial
JAMA, 301 (11), 1131-9
DOI 10.1001/jama.301.11.1131, PubMed 19293413

Ose L, Budinski D, Hounslow N, Arneson V (2009)
Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia
Curr Med Res Opin, 25 (11), 2755-64
DOI 10.1185/03007990903290886, PubMed 19785568

Ose L, Budinski D, Hounslow N, Arneson V (2009)
Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia
Atherosclerosis, 210 (1), 202-8
DOI 10.1016/j.atherosclerosis.2009.12.009, PubMed 20080236

Tobin KA, Holven KB, Retterstøl K, Strøm E, Ose L, Aukrust P, Nenseter MS (2009)
Cystatin C levels in plasma and peripheral blood mononuclear cells among hyperhomocysteinaemic subjects: effect of treatment with B-vitamins
Br J Nutr, 102 (12), 1783-9
DOI 10.1017/S0007114509991048, PubMed 19682403

Publications 2008

Holven KB, Aukrust P, Retterstøl K, Otterdal K, Bjerkeli V, Ose L, Nenseter MS, Halvorsen B (2008)
The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects
J Nutr, 138 (11), 2070-5
DOI 10.3945/jn.108.090704, PubMed 18936200

Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE (2008)
Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening
Community Genet, 11 (1), 26-35
DOI 10.1159/000111637, PubMed 18196915

Nenseter MS, Ueland T, Retterstøl K, Strøm E, Mørkrid L, Landaas S, Ose L, Aukrust P, Holven KB (2008)
Dysregulated RANK ligand/RANK axis in hyperhomocysteinemic subjects: effect of treatment with B-vitamins
Stroke, 40 (1), 241-7
DOI 10.1161/STROKEAHA.108.522995, PubMed 19008470

Ose L (2008)
The real code of leonardo da vinci
Curr Cardiol Rev, 4 (1), 60-2
DOI 10.2174/157340308783565401, PubMed 19924278

Publications 2007

Feldman T, Ose L, Shah A, Zakson M, Meehan A, Johnson-Levonas AO, Maccubbin D, Tribble DL, Veltri E, Mitchel Y (2007)
Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome
Metab Syndr Relat Disord, 5 (1), 13-21
DOI 10.1089/met.2006.0033, PubMed 18370810

Hamrin MG, Breistein TK, Ose L, Ottestad IO (2007)
Sunne kaker
Damm, [Oslo], 127 s.
BIBSYS 071410058, ISBN 978-82-04-13869-9

Leren TP, Manshaus TE, Ose L, Berge KE (2007)
[Lipid profile in children and adolescents with familial hypercholesterolemia]
Tidsskr Nor Laegeforen, 127 (18), 2363-6
PubMed 17895939

Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, Musliner T, Vytorin Extension Study Group (2007)
A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet
Int J Clin Pract, 61 (9), 1469-80
DOI 10.1111/j.1742-1241.2007.01402.x, PubMed 17655686

Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T (2007)
Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques
Clin Ther, 29 (11), 2419-32
DOI 10.1016/j.clinthera.2007.10.004, PubMed 18158082

Stein EA, Ose L, Retterstøl K, Tonstad S, Schleman M, Harris S, Sager P (2007)
Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia
J Clin Lipidol, 1 (4), 280-6
DOI 10.1016/j.jacl.2007.07.003, PubMed 21291692

Tonstad S, Retterstøl K, Ose L, Ohman KP, Lindberg MB, Svensson M (2007)
The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin
Metabolism, 56 (9), 1285-92
DOI 10.1016/j.metabol.2007.05.003, PubMed 17697874

Publications 2006

Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, Retterstøl K (2006)
Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia
Atherosclerosis, 189 (2), 451-7
DOI 10.1016/j.atherosclerosis.2006.01.002, PubMed 16466729

Amundsen AL, Khoury J, Sandset PM, Seljeflot I, Ose L, Tonstad S, Henriksen T, Retterstøl K, Iversen PO (2006)
Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia
Thromb Res, 120 (1), 21-7
DOI 10.1016/j.thromres.2006.07.001, PubMed 16914186

Berge KE, Ose L, Leren TP (2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
Arterioscler Thromb Vasc Biol, 26 (5), 1094-100
DOI 10.1161/01.ATV.0000204337.81286.1c, PubMed 16424354

Frich JC, Ose L, Malterud K, Fugelli P (2006)
Perceived vulnerability to heart disease in patients with familial hypercholesterolemia: a qualitative interview study
Ann Fam Med, 4 (3), 198-204
DOI 10.1370/afm.529, PubMed 16735520

Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K (2006)
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy
Clin Pharmacol Ther, 79 (6), 532-9
DOI 10.1016/j.clpt.2006.02.014, PubMed 16765141

Holven KB, Aukrust P, Pedersen TM, Ose L, Nenseter MS (2006)
Enhanced platelet activation in hyperhomocysteinemic individuals
J Thromb Haemost, 5 (1), 193-5
DOI 10.1111/j.1538-7836.2006.02275.x, PubMed 17059422

Holven KB, Aukrust P, Retterstol K, Hagve TA, Mørkrid L, Ose L, Nenseter MS (2006)
Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects
Scand J Clin Lab Invest, 66 (1), 45-54
DOI 10.1080/00335510500429821, PubMed 16464786

Holven KB, Halvorsen B, Bjerkeli V, Damås JK, Retterstøl K, Mørkrid L, Ose L, Aukrust P, Nenseter MS (2006)
Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects
Stroke, 37 (7), 1731-6
DOI 10.1161/01.STR.0000226465.84561.cb, PubMed 16728689

Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y (2006)
Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis
Curr Med Res Opin, 22 (5), 823-35
DOI 10.1185/030079906X100131, PubMed 16709304

Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao EA, Yin DD, Borgström F, Jönsson L (2006)
Lipid management and cholesterol goal attainment in Norway
Am J Cardiovasc Drugs, 6 (2), 121-8
DOI 10.2165/00129784-200606020-00006, PubMed 16555865

Ottestad IO, Halvorsen B, Balstad TR, Otterdal K, Borge GI, Brosstad F, Myhre AM, Ose L, Nenseter MS, Holven KB (2006)
Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux
J Nutr, 136 (4), 877-81
DOI 10.1093/jn/136.4.877, PubMed 16549444

Ueland T, Vissers MN, Wiegman A, Rodenburg J, Hutten B, Gullestad L, Ose L, Rifai N, Ridker PM, Kastelein JJ, Aukrust P, Semb AG (2006)
Increased inflammatory markers in children with familial hypercholesterolaemia
Eur J Clin Invest, 36 (3), 147-52
DOI 10.1111/j.1365-2362.2006.01613.x, PubMed 16506958

Publications 2005

Balstad TR, Holven KB, Ottestad IO, Otterdal K, Halvorsen B, Myhre AM, Ose L, Nenseter MS (2005)
Altered composition of HDL3 in FH subjects causing a HDL subfraction with less atheroprotective function
Clin Chim Acta, 359 (1-2), 171-8
DOI 10.1016/j.cccn.2005.03.050, PubMed 15936009

Holven KB, Damås JK, Yndestad A, Waehre T, Ueland T, Halvorsen B, Heggelund L, Sandberg WJ, Semb AG, Frøland SS, Ose L, Nenseter MS, Aukrust P (2005)
Chemokines in children with heterozygous familiar hypercholesterolemia: selective upregulation of RANTES
Arterioscler Thromb Vasc Biol, 26 (1), 200-5
DOI 10.1161/01.ATV.0000193619.67288.ed, PubMed 16254204

Ose L, Bergei CS, Bøe J (2005)
Godt for ganen, godt for hjertet: maten som gir deg et bedre liv
Cappelen, Oslo (3. utg.), 175 s.
BIBSYS 050189530, ISBN 82-02-24399-8

Publications 2004

Amundsen AL, Ntanios F, Put Nv, Ose L (2004)
Long-term compliance and changes in plasma lipids, plant sterols and carotenoids in children and parents with FH consuming plant sterol ester-enriched spread
Eur J Clin Nutr, 58 (12), 1612-20
DOI 10.1038/sj.ejcn.1602015, PubMed 15199384

Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group (2004)
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia
Clin Ther, 26 (11), 1758-73
DOI 10.1016/j.clinthera.2004.11.016, PubMed 15639688

Blomhoff S, Holven KB, Brosstad F, Ose L, Nenseter MS (2004)
Psychological factors and cardiovascular disease
J Thromb Haemost, 2 (1), 201-3
DOI 10.1111/j.1538-7836.2004.0562g.x, PubMed 14717990

Leren TP, Manshaus T, Ose L (2004)
[A family-based strategy for diagnosing familial hypercholesterolemia]
Tidsskr Nor Laegeforen, 124 (9), 1228-9
PubMed 15131703

Ose L (2004)
Diagnostic, clinical, and therapeutic aspects of familial hypercholesterolemia in children
Semin Vasc Med, 4 (1), 51-7
DOI 10.1055/s-2004-822986, PubMed 15199433

Ose L (2004)
Diabetes og lipidforstyrrelse
In Diabeteshåndboken, Gyldendal akademisk, Oslo, s. 270-275
BIBSYS 041965299

Svilaas A, Sakhi AK, Andersen LF, Svilaas T, Ström EC, Jacobs DR, Ose L, Blomhoff R (2004)
Intakes of antioxidants in coffee, wine, and vegetables are correlated with plasma carotenoids in humans
J Nutr, 134 (3), 562-7
DOI 10.1093/jn/134.3.562, PubMed 14988447

Publications 2003

Davidson MH, Ose L, Frohlich J, Scott RS, Dujovne CA, Escobar ID, Bertolami MC, Cihon F, Maccubbin DL, Mercuri M (2003)
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups
Clin Cardiol, 26 (11), 509-14
DOI 10.1002/clc.4960261106, PubMed 14640465

Fretheim A, Oxman AD, Bjørndal A, Dyrdal A, Golding M, Ose L, Reikvam D, Teisberg P (2003)
[Shortcomings and strength of practice guidelines]
Tidsskr Nor Laegeforen, 123 (11), 1566-7
PubMed 12822025

Holven KB, Halvorsen B, Schulz H, Aukrust P, Ose L, Nenseter MS (2003)
Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinaemic subjects
Eur J Clin Invest, 33 (7), 555-60
DOI 10.1046/j.1365-2362.2003.01189.x, PubMed 12814391

Holven KB, Haugstad TS, Holm T, Aukrust P, Ose L, Nenseter MS (2003)
Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects
Br J Nutr, 89 (3), 359-63
DOI 10.1079/BJN2002779, PubMed 12628031

Holven KB, Myhre AM, Aukrust P, Hagve TA, Ose L, Nenseter MS (2003)
Patients with familial hypercholesterolaemia show enhanced spontaneous chemokine release from peripheral blood mononuclear cells ex vivo. Dependency of xanthomas/xanthelasms, smoking and gender
Eur Heart J, 24 (19), 1756-62
DOI 10.1016/s0195-668x(03)00467-6, PubMed 14522571

Holven KB, Scholz H, Halvorsen B, Aukrust P, Ose L, Nenseter MS (2003)
Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells
J Nutr, 133 (11), 3588-91
DOI 10.1093/jn/133.11.3588, PubMed 14608078

McCrindle BW, Ose L, Marais AD (2003)
Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial
J Pediatr, 143 (1), 74-80
DOI 10.1016/S0022-3476(03)00186-0, PubMed 12915827

Publications 2002

Amundsen AL, Ose L, Nenseter MS, Ntanios FY (2002)
Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia
Am J Clin Nutr, 76 (2), 338-44
DOI 10.1093/ajcn/76.2.338, PubMed 12145004

de Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, Kastelein JJ, Simvastatin in Children Study Group (2002)
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin
Circulation, 106 (17), 2231-7
DOI 10.1161/01.cir.0000035247.42888.82, PubMed 12390953

Fretheim A, Bjørndal A, Oxman AD, Dyrdal A, Golding M, Ose L, Reikvam A, Teisberg P (2002)
[Guidelines for pharmacological primary prevention of cardiovascular diseases--who should be treated?]
Tidsskr Nor Laegeforen, 122 (23), 2277-81
PubMed 12448268

Fretheim A, Bjørndal A, Oxman AD, Dyrdal A, Golding M, Ose L, Reikvam A, Teisberg P (2002)
[Which antihypertensive drugs should be used in the primary prevention of cardiovascular disease?]
Tidsskr Nor Laegeforen, 122 (23), 2283-6
PubMed 12448269

Fretheim A, Bjørndal A, Oxman AD, Dyrdal A, Golding M, Ose L, Reikvam A, Teisberg P (2002)
[Which cholesterol-lowering drugs should be used in the primary prevention of cardiovascular disease?]
Tidsskr Nor Laegeforen, 122 (23), 2287-8
PubMed 12448270

Holven KB, Aukrust P, Holm T, Ose L, Nenseter MS (2002)
Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects
Arterioscler Thromb Vasc Biol, 22 (4), 699-703
DOI 10.1161/01.atv.0000013288.35930.90, PubMed 11950713

Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW, Rosuvastatin Investigators Group (2002)
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
Am Heart J, 144 (6), 1044-51
DOI 10.1067/mhj.2002.128049, PubMed 12486429

Ose L (2002)
[Müller-Harbitz disease--familial hypercholesterolemia]
Tidsskr Nor Laegeforen, 122 (9), 924-5
PubMed 12082837

Ose L (2002)
Familial hypercholesterolemia from children to adults
Cardiovasc Drugs Ther, 16 (4), 289-93
DOI 10.1023/a:1021773724477, PubMed 12652097

Svilaas A, Ström EC, Svilaas T, Borgejordet A, Thoresen M, Ose L (2002)
Reproducibility and validity of a short food questionnaire for the assessment of dietary habits
Nutr Metab Cardiovasc Dis, 12 (2), 60-70
PubMed 12189905

Publications 2001

Guttormsen AB, Ueland PM, Kruger WD, Kim CE, Ose L, Følling I, Refsum H (2001)
Disposition of homocysteine in subjects heterozygous for homocystinuria due to cystathionine beta-synthase deficiency: relationship between genotype and phenotype
Am J Med Genet, 100 (3), 204-13
DOI 10.1002/ajmg.1247, PubMed 11343305

Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, Gullestad L, Hagve TA, Svilaas A, Ose L, Nenseter MS (2001)
Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects
Am J Med, 110 (7), 536-42
DOI 10.1016/s0002-9343(01)00696-9, PubMed 11343667

Lee MH, Gordon D, Ott J, Lu K, Ose L, Miettinen T, Gylling H, Stalenhoef AF, Pandya A, Hidaka H, Brewer B, Kojima H, Sakuma N, Pegoraro R, Salen G, Patel SB (2001)
Fine mapping of a gene responsible for regulating dietary cholesterol absorption; founder effects underlie cases of phytosterolaemia in multiple communities
Eur J Hum Genet, 9 (5), 375-84
DOI 10.1038/sj.ejhg.5200628, PubMed 11378826

Leren TP, Tonstad S, Ose L (2001)
[Familial hypercholesterolemia--prognosis and treatment]
Tidsskr Nor Laegeforen, 121 (13), 1635
PubMed 11446054

Leren TP, Tonstad S, Ose L (2001)
[Genetic screening and treatment in familial hypercholesterolemia]
Tidsskr Nor Laegeforen, 121 (13), 1635-6
PubMed 11446055

Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, Ose L, Stalenhoef AF, Mietinnen T, Bjorkhem I, Bruckert E, Pandya A, Brewer HB, Salen G, Dean M, Srivastava A, Patel SB (2001)
Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively
Am J Hum Genet, 69 (2), 278-90
DOI 10.1086/321294, PubMed 11452359

Ose L, Bergei CS, Bøe J (2001)
Godt for ganen, godt for hjertet: sunn mat, også for deg med høyt kolesterol
Cappelen, Oslo (2. utg.), 167 s.
BIBSYS 020141122, ISBN 82-02-21424-6

Svilaas A, Ose L, Risberg K, Thoresen M (2001)
[Treatment goals for blood lipids in high risk patients of atherosclerotic disease]
Tidsskr Nor Laegeforen, 121 (9), 1059-63
PubMed 11354882

Tonstad S, Strøm EC, Bergei CS, Ose L, Christophersen B (2001)
Serum cholesterol response to replacing butter with a new trans-free margarine in hypercholesterolemic subjects
Nutr Metab Cardiovasc Dis, 11 (5), 320-6
PubMed 11887429

Publications 2000

Björn Lundahl, Leren TP, Ose L, Hamsten A, Karpe F (2000)
A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP -493G/T) influences lipoprotein phenotype in familial hypercholesterolemia
Arterioscler Thromb Vasc Biol, 20 (7), 1784-8
DOI 10.1161/01.atv.20.7.1784, PubMed 10894817

Davidson MH, Stein EA, Hunninghake DB, Ose L, Dujovne CA, Insull W, Bertolami M, Weiss SR, Kastelein JJ, Scott RS, Campodónico S, Escobar ID, Schrott HG, Bays H, Stepanavage ME, Wu M, Tate AC, Melino MR, Kush D, Mercuri M, Mitchel YB, Worldwide Expanded Dose Simvastatin Study Group (2000)
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia
Nutr Metab Cardiovasc Dis, 10 (5), 253-62
PubMed 11213534

Kastelein JJ, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, Habib R, Dujovne CA, Crouse JR, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB (2000)
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels
Am J Cardiol, 86 (2), 221-3
DOI 10.1016/s0002-9149(00)00942-5, PubMed 10913488

Nenseter MS, Østerud B, Larsen T, Strøm E, Bergei C, Hewitt S, Holven KB, Hagve TA, Mjøs SA, Solvang M, Pettersen J, Opstvedt J, Ose L (2000)
Effect of Norwegian fish powder on risk factors for coronary heart disease among hypercholesterolemic individuals
Nutr Metab Cardiovasc Dis, 10 (6), 323-30
PubMed 11302007

Ose L, Davidson MH, Stein EA, Kastelein JJ, Scott RS, Hunninghake DB, Campodonico S, Insull W, Escobar ID, Schrott HG, Stepanavage ME, Wu M, Tate AC, Melino MR, Mercuri M, Mitchel YB (2000)
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group
Clin Cardiol, 23 (1), 39-46
DOI 10.1002/clc.4960230108, PubMed 10680028

Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B (2000)
Cerivastatin gender effect: sub-analyses of results from a multinational, randomised, double-blind study. Cerivastatin Study Group
Curr Med Res Opin, 16 (2), 80-7
PubMed 10893651

Svilaas A, Bergei CS, Strøm EC, Ose L, Walsøe HK (2000)
[The diet of patients with atherosclerotic disease compared with the standard diet in the population]
Tidsskr Nor Laegeforen, 120 (22), 2618-24
PubMed 11077504

Svilaas A, Risberg K, Thoresen M, Ose L (2000)
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice
Am J Cardiol, 86 (11), 1250-3, A6
DOI 10.1016/s0002-9149(00)01212-1, PubMed 11090801

Svilaas A, Walsöe HK, Ose L (2000)
Application of simple lipid treatment goals in patients with atherosclerotic disease
Nutr Metab Cardiovasc Dis, 10 (2), 71-8
PubMed 10919171

Tonstad S, Joakimsen O, Leren TP, Ose L (2000)
Does maternal or paternal heredity affect carotid atherosclerosis in children with familial hypercholesterolaemia?
Acta Paediatr, 89 (12), 1490-2
DOI 10.1080/080352500456705, PubMed 11195242

Publications 1999

Crouse JR, Frohlich J, Ose L, Mercuri M, Tobert JA (1999)
Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
Am J Cardiol, 83 (10), 1476-7, A7
DOI 10.1016/s0002-9149(99)00153-8, PubMed 10335764

Hanefeld M, Deslypere JP, Ose L, Durrington PN, Farnier M, Schmage N (1999)
Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study
J Int Med Res, 27 (3), 115-29
DOI 10.1177/030006059902700302, PubMed 10505301

Ose L (1999)
An update on familial hypercholesterolaemia
Ann Med, 31 Suppl 1, 13-8
PubMed 10342495

Ose L (1999)
An update on familial hypercholesterolaemia
Ann Med, 31 (sup1), 13-18
DOI 10.1080/07853890.1999.11904394, PubMed 28850282

Ose L, Bergei CS (1999)
Godt for ganen, godt for hjertet: sunn mat, også for deg med høyt kolesterol
Grøndahl Dreyer, Oslo, 167 s.
BIBSYS 991519612, ISBN 82-504-2553-7

Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B (1999)
Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group
Curr Med Res Opin, 15 (3), 228-40
DOI 10.1185/03007999909114095, PubMed 10621930

Rødningen OK, Tonstad S, Medh JD, Chappell DA, Ose L, Leren TP (1999)
Phenotypic consequences of a deletion of exons 2 and 3 of the LDL receptor gene
J Lipid Res, 40 (2), 213-20
PubMed 9925649

Rødningen OK, Tonstad S, Saugstad OD, Ose L, Leren TP (1999)
Mutant transcripts of the LDL receptor gene: mRNA structure and quantity
Hum Mutat, 13 (3), 186-96
DOI 10.1002/(SICI)1098-1004(1999)13:3<186::AID-HUMU2>3.0.CO;2-K, PubMed 10090473

Tonstad S, Gørbitz C, Sivertsen M, Ose L (1999)
Under-reporting of dietary intake by smoking and non-smoking subjects counselled for hypercholesterolaemia
J Intern Med, 245 (4), 337-44
DOI 10.1046/j.1365-2796.1999.00450.x, PubMed 10356595

Publications 1998

Davignon J, Hanefeld M, Nakaya N, Hunninghake DB, Insull W, Ose L (1998)
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies
Am J Cardiol, 82 (4B), 32J-39J
DOI 10.1016/s0002-9149(98)00435-4, PubMed 9737644

Ose L, Kastelein JJP, Scott R, Stein EA, Campodonico S, Escobar ID, Tate AC, Corsetti L, Shahane A, Mitchel YB, Mercuri M, WSEDP Res Grp (1998)
Efficacy and six-month safety of simvastatin 80 mg/day: Results from the worldwide simvastatin expanded dose program (WSEDP)
Nutr. Metab. Carbiovasc. Dis., 8 (3), 135-143

Ose L, Vollebaek LE, Tonstad S (1998)
[Attitude to genetic screening for familial hypercholesterolemia]
Tidsskr Nor Laegeforen, 118 (10), 1578-81
PubMed 9615587

Rødningen OK, Tonstad S, Ose L, Berg K, Leren TP (1998)
Effects of a 9.6-kb deletion of the LDL receptor gene (FH Helsinki) on structure and levels of mRNA
Hum Mutat, 12 (2), 95-102
DOI 10.1002/(SICI)1098-1004(1998)12:2<95::AID-HUMU4>3.0.CO;2-E, PubMed 9671270

Sundt E, Ose L, Tonstad S (1998)
[Referrals to the Lipid clinic--"appropriate" patients with inadequate anamnesis]
Tidsskr Nor Laegeforen, 118 (5), 749-52
PubMed 9528374

Tonstad S, Joakimsen O, Stensland-Bugge E, Ose L, Bønaa KH, Leren TP (1998)
Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects
Eur J Clin Invest, 28 (12), 971-9
DOI 10.1046/j.1365-2362.1998.00399.x, PubMed 9893006

Tonstad S, Refsum H, Ose L, Ueland PM (1998)
The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine
J Pediatr, 132 (2), 365-8
DOI 10.1016/s0022-3476(98)70465-2, PubMed 9506661

Publications 1997

Kim CE, Gallagher PM, Guttormsen AB, Refsum H, Ueland PM, Ose L, Folling I, Whitehead AS, Tsai MY, Kruger WD (1997)
Functional modeling of vitamin responsiveness in yeast: a common pyridoxine-responsive cystathionine beta-synthase mutation in homocystinuria
Hum Mol Genet, 6 (13), 2213-21
DOI 10.1093/hmg/6.13.2213, PubMed 9361025

Leren TP, Bakken KS, Daum U, Ose L, Berg K, Assmann G, von Eckardstein A (1997)
Heterozygosity for apolipoprotein A-I(R160L)Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I
J Lipid Res, 38 (1), 121-31
PubMed 9034206

Leren TP, Bakken KS, Rødningen OK, Gundersen KE, Sundvold H, Berg K, Tonstad S, Ose L (1997)
[Application of gene technology in the diagnosis of familial hypercholesterolemia]
Tidsskr Nor Laegeforen, 117 (5), 678-81
PubMed 9102960

Leren TP, Ose L (1997)
[Is there a need for genetic/molecular diagnosis of familial hypercholesterolemia?]
Tidsskr Nor Laegeforen, 117 (5), 681-3
PubMed 9102961

Leren TP, Tonstad S, Gundersen KE, Bakken KS, Rødningen OK, Sundvold H, Ose L, Berg K (1997)
Molecular genetics of familial hypercholesterolaemia in Norway
J Intern Med, 241 (3), 185-94
DOI 10.1046/j.1365-2796.1997.78119000.x, PubMed 9104431

Svilaas A, Bye P, Strøm EC, Kolbjørnsen O, Tonstad S, Ose L (1997)
[What happens with patients after participation in a clinical trial?]
Tidsskr Nor Laegeforen, 117 (28), 4065-9
PubMed 9441437

Tonstad S, Leren TP, Ose L (1997)
[Diagnosis and treatment of severe hyperlipidemia]
Tidsskr Nor Laegeforen, 117 (29), 4241-4
PubMed 9441469

Urdal P, Leren TP, Tonstad S, Lund PK, Ose L (1997)
Flow cytometric measurement of low density lipoprotein receptor activity validated by DNA analysis in diagnosing heterozygous familial hypercholesterolemia
Cytometry, 30 (5), 264-8
PubMed 9383100

Publications 1996

Gundersen KE, Solberg K, Rødningen OK, Tonstad S, Ose L, Berg K, Leren TP (1996)
Two novel missense mutations in the LDL receptor gene causing familial hypercholesterolemia
Clin Genet, 49 (2), 85-7
DOI 10.1111/j.1399-0004.1996.tb04333.x, PubMed 8740918

Halvorsen B, Brude I, Drevon CA, Nysom J, Ose L, Christiansen EN, Nenseter MS (1996)
Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein
J Lipid Res, 37 (7), 1591-600
PubMed 8827529

Leren TP, Sundvold H, Rodningen OK, Tonstad S, Solberg K, Ose L, Berg K (1996)
Screening for known mutations in the LDL receptor gene causing familial hypercholesterolemia (vol 95, pg 671, 1995)
Hum. Genet., 97 (2), 268
DOI 10.1007/BF02265281

Lütjohann D, Björkhem I, Ose L (1996)
Phytosterolaemia in a Norwegian family: diagnosis and characterization of the first Scandinavian case
Scand J Clin Lab Invest, 56 (3), 229-40
DOI 10.3109/00365519609088612, PubMed 8761527

Nenseter MS, Volden V, Berg T, Drevon CA, Ose L, Tonstad S (1996)
Effect of hormone replacement therapy on the susceptibility of low-density lipoprotein to oxidation among postmenopausal hypercholesterolaemic women
Eur J Clin Invest, 26 (12), 1062-8
DOI 10.1046/j.1365-2362.1996.390593.x, PubMed 9013080

Ose L (1996)
Simvastatin-fluvastatin comparative study - Reply
Clin. Drug Invest., 11 (6), 363-364

Ose L (1996)
Simvastatin-fluvastatin comparative study - Continued - Reply
Clin. Drug Invest., 12 (1), 57

Ose L (1996)
Familiær hyperkolesterolemi: et orienteringshefte for helsepersonell og pasienter med familiær hyperkolesterolemi
Lipidklinikken, Rikshospitalet, Oslo ([Ny utg.]), 15 s.
BIBSYS 960697829

Retterstøl K, Stugaard M, Gørbitz C, Ose L (1996)
Results of intensive long-term treatment of familial hypercholesterolemia
Am J Cardiol, 78 (12), 1369-74
DOI 10.1016/s0002-9149(96)00649-2, PubMed 8970408

Sundvold H, Solberg K, Tonstad S, Rødningen OK, Ose L, Berg K, Leren TP (1996)
A common missense mutation (C210G) in the LDL receptor gene among Norwegian familial hypercholesterolemia subjects
Hum Mutat, 7 (1), 70-1
DOI 10.1002/(SICI)1098-1004(1996)7:1<70::AID-HUMU12>3.0.CO;2-P, PubMed 8664907

Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, Bønaa KH (1996)
Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects
Arterioscler Thromb Vasc Biol, 16 (8), 984-91
DOI 10.1161/01.atv.16.8.984, PubMed 8696963

Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L (1996)
Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia
J Pediatr, 129 (1), 42-9
DOI 10.1016/s0022-3476(96)70188-9, PubMed 8757561

Tonstad S, Ose L (1996)
Colestipol tablets in adolescents with familial hypercholesterolaemia
Acta Paediatr, 85 (9), 1080-2
DOI 10.1111/j.1651-2227.1996.tb14221.x, PubMed 8888922

Tonstad S, Refsum H, Sivertsen M, Christophersen B, Ose L, Ueland PM (1996)
Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives
Pediatr Res, 40 (1), 47-52
DOI 10.1203/00006450-199607000-00009, PubMed 8798245

Tonstad S, Sivertsen M, Aksnes L, Ose L (1996)
Low dose colestipol in adolescents with familial hypercholesterolaemia
Arch Dis Child, 74 (2), 157-60
DOI 10.1136/adc.74.2.157, PubMed 8660081

Tonstad S, Sundt E, Ose L, Hagve TA, Fruchart JC, Bard JM, Edén S (1996)
The effect of growth hormone on low-density lipoprotein cholesterol and lipoprotein (a) levels in familial hypercholesterolemia
Metabolism, 45 (11), 1415-21
DOI 10.1016/s0026-0495(96)90124-9, PubMed 8931648

Publications 1995

Bard JM, Dallongeville J, Hagen E, Pfister P, Ose L, Fruchart JC, Duriez P (1995)
Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition
Metabolism, 44 (11), 1447-54
DOI 10.1016/0026-0495(95)90145-0, PubMed 7476333

Bard JM, Ose L, Hagen E, Duriez P, Pfister P, Fruchart JC, Dallongeville J (1995)
Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group
Am J Cardiol, 76 (2), 65A-70A
DOI 10.1016/s0002-9149(05)80021-9, PubMed 7604802

BARD JM, OSE L, HAGEN E, DURIEZ P, PFISTER P, FRUCHART JC, DALLONGEVILLE J (1995)
CHANGES IN PLASMA APOLIPOPROTEIN B-CONTAINING LIPOPARTICLE LEVELS FOLLOWING THERAPY WITH FLUVASTATIN AND CHOLESTYRAMINE
Am. J. Cardiol., 76 (2), A65-A70

Gørbitz C, Bergei CS, Sivertsen M, Ose L, Abyholm T (1995)
[Diet and lipid status in pregnant women]
Tidsskr Nor Laegeforen, 115 (11), 1358-60
PubMed 7770831

Leren TP, Rødningen OK, Tonstad S, Røsby O, Urdal P, Ose L (1995)
Identification of the apo B-3500 mutation in the Norwegian population
Scand J Clin Lab Invest, 55 (3), 217-21
DOI 10.3109/00365519509089616, PubMed 7638555

Leren TP, Solberg K, Rødningen OK, Tonstad S, Ose L (1995)
Two novel point mutations in the EGF precursor homology domain of the LDL receptor gene causing familial hypercholesterolemia
Hum Genet, 96 (2), 241-2
DOI 10.1007/BF00207391, PubMed 7635482

Leren TP, Sundvold H, Rødningen OK, Tonstad S, Solberg K, Ose L, Berg K (1995)
Screening for known mutations in the LDL receptor gene causing familial hypercholesterolemia
Hum Genet, 95 (6), 671-6
DOI 10.1007/BF00209485, PubMed 7789953

Løhne K, Urdal P, Leren TP, Tonstad S, Ose L (1995)
Standardization of a flow cytometric method for measurement of low-density lipoprotein receptor activity on blood mononuclear cells
Cytometry, 20 (4), 290-5
DOI 10.1002/cyto.990200404, PubMed 7587716

Nenseter MS, Volden V, Berg T, Drevon CA, Ose L, Tonstad S (1995)
No effect of beta-carotene supplementation on the susceptibility of low density lipoprotein to in vitro oxidation among hypercholesterolaemic, postmenopausal women
Scand J Clin Lab Invest, 55 (6), 477-85
DOI 10.3109/00365519509075385, PubMed 8571077

NORDESTGAARD BG, JAUHIAINEN M, WIKLUND O, FAGER G, STENDER S, DREVON CA, OSE L (1995)
FIRST ANNUAL COPENHAGEN ATHEROSCLEROSIS CONFERENCE
Arterioscl. Thromb. Vasc. Biol., 15 (10), 1787-1790

Ose L (1995)
[Treatment of hyperlipidemia. Guidelines for treatment of hyperlipidemia for secondary prevention of ischemic heart disease]
Tidsskr Nor Laegeforen, 115 (29), 3629-31
PubMed 8539720

Ose L, Scott R (1995)
Erratum to Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia
Clin Drug Investig, 10 (6), 343
DOI 10.1007/BF03259374, PubMed 27519335

Ose L, Scott R, Grossman L (1995)
Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia
Clin Drug Investig, 10 (3), 127-38
DOI 10.2165/00044011-199510030-00001, PubMed 27519196

Ose L, Søvik O, Vesterhus P, Wefring KW, Aagenaes O (1995)
[Familial hypercholesterolemia in children. A management program. Procedures for diagnosis and treatment in our pediatric departments]
Tidsskr Nor Laegeforen, 115 (28), 3514
PubMed 7491607

Ose L, Tonstad S (1995)
The detection and management of dyslipidaemia in children and adolescents
Acta Paediatr, 84 (11), 1213-5
PubMed 8580613

Ose L, Tonstad S, Vesterhus P, Wefring KW (1995)
[Diagnosis and treatment of familial hypercholesterolemia in children and adolescents]
Tidsskr Nor Laegeforen, 115 (28), 3499-503
PubMed 7491603

Ose L, Aass B, Christophersen B (1995)
[A rapid analysis of the lipid profile. A comparative study of different analytical methods for determination of blood lipids]
Tidsskr Nor Laegeforen, 115 (28), 3487-9
PubMed 7491599

Samdal F, Birkeland KI, Ose L, Amland PF (1995)
Effect of large-volume liposuction on sex hormones and glucose- and lipid metabolism in females
Aesthetic Plast Surg, 19 (2), 131-5
DOI 10.1007/BF00450248, PubMed 7598023

Seedorf U, Wiebusch H, Muntoni S, Christensen NC, Skovby F, Nickel V, Roskos M, Funke H, Ose L, Assmann G (1995)
A novel variant of lysosomal acid lipase (Leu336-->Pro) associated with acid lipase deficiency and cholesterol ester storage disease
Arterioscler Thromb Vasc Biol, 15 (6), 773-8
DOI 10.1161/01.atv.15.6.773, PubMed 7773732

TONSTAD S, BING RF, FROHLICH J, KARPOV Y, OSE L, ROMICS L, STURMER W, PAWSEY SD, ZHANG IX (1995)
EFFECTIVENESS OF COLESTIPOL TABLETS VS GRANULES IN PATIENTS WITH MODERATE TO SEVERE HYPERCHOLESTEROLEMIA
Clin. Drug Invest., 10 (5), 257-263
DOI 10.2165/00044011-199510050-00002

TONSTAD S, DELANGE P, SIVERTSEN M, OSE L (1995)
PHYSICAL-FITNESS AND FIBRINOGEN LEVELS AMONG HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN
Nutr. Metab. Carbiovasc. Dis., 5 (2), 93-97

Tonstad S, Holdaas H, Gørbitz C, Ose L (1995)
Is dietary intervention effective in post-transplant hyperlipidaemia?
Nephrol Dial Transplant, 10 (1), 82-5
PubMed 7724035

Tonstad S, Leren TP, Sivertsen M, Ose L (1995)
Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway
Arterioscler Thromb Vasc Biol, 15 (8), 1009-14
DOI 10.1161/01.atv.15.8.1009, PubMed 7627689

Tonstad S, Ose L, Gørbitz C, Djøseland O, Bard JM, Fruchart JC (1995)
Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women
J Intern Med, 238 (1), 39-47
DOI 10.1111/j.1365-2796.1995.tb00897.x, PubMed 7608645

Tonstad S, Vollebaek LE, Ose L (1995)
Screening for familial hypercholesterolaemia in relatives
Lancet, 346 (8987), 1438
DOI 10.1016/s0140-6736(95)92461-2, PubMed 7475864

Publications 1994

Gørbitz C, Ose L (1994)
[Diet therapy of hypercholesterolemia. Can the diet of persons who already follow a cholesterol-lowering diet be further improved by guidelines given by a clinical nutritionist?]
Tidsskr Nor Laegeforen, 114 (18), 2106-8
PubMed 7992266

Gørbitz C, Ose L (1994)
[Iron status in postmenopausal women]
Tidsskr Nor Laegeforen, 114 (4), 436-8
PubMed 8009479

Hagen E, Istad H, Ose L, Bodd E, Eriksen HM, Selvig V, Bard JM, Fruchart JC, Borge M, Wolf MC (1994)
Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine
Eur J Clin Pharmacol, 46 (5), 445-9
DOI 10.1007/BF00191909, PubMed 7957541

Leren TP, Solberg K, Rødningen OK, Tonstad S, Ose L (1994)
Two founder mutations in the LDL receptor gene in Norwegian familial hypercholesterolemia subjects
Atherosclerosis, 111 (2), 175-82
DOI 10.1016/0021-9150(94)90091-4, PubMed 7718019

Nenseter MS, Volden V, Tonstad S, Gudmundsen O, Ose L, Drevon CA (1994)
Modification of low density lipoprotein in relation to intake of fatty acids and antioxidants
World Rev Nutr Diet, 75, 144-8
DOI 10.1159/000423570, PubMed 7871817

Solberg K, Rødningen OK, Tonstad S, Ose L, Leren TP (1994)
Familial hypercholesterolaemia caused by a non-sense mutation in codon 329 of the LDL receptor gene
Scand J Clin Lab Invest, 54 (8), 605-9
DOI 10.3109/00365519409087539, PubMed 7709162

Tonstad S, Gørbitz C, Ose L, Malt UF (1994)
[A comparison between lovastatin and pravastatin--effects on lipids, sleep and quality of life in primary hyperlipidemia]
Tidsskr Nor Laegeforen, 114 (19), 2262-4
PubMed 7992293

Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, Golay A, Reitsma J, Del Bufalo A, Pasotti E (1994)
The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia
Eur J Clin Pharmacol, 46 (5), 405-10
DOI 10.1007/BF00191901, PubMed 7957533

TONSTAD S, SIVERTSEN M, LEREN TP, ROSBY O, OSE L (1994)
RESPONSIVENESS TO DIETARY INDULGENCE AMONG PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
Nutr. Metab. Carbiovasc. Dis., 4 (3), 159-162

Publications 1993

FERDER LF, BERTOLAMI MC, GIANNINI SD, CORTAZAR J, OBONARELLANO A, AGNER E, LETH A, MATTILA S, TIKKANEN MJ, FRUCHART JC, DUTZ W, GUNTHER KH, GUTSCHKER A, HEINEMAN G, MORICKE KR, REUTER W, STEINHAGENTHIESSEN E, KRANKENHAUS MB, TOUTOUZAS P, TAI YT, RUBENSTEIN A, RULL J, OSE L, GARMENDIA F, CARRAGETA MO et al. (1993)
A MULTICENTER COMPARATIVE TRIAL OF LOVASTATIN AND PRAVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
Am. J. Cardiol., 71 (10), 810-815

Hagve TA, Furuset T, Christophersen B, Ose L (1993)
[Apolipoprotein E phenotyping--useful in the study of hyperlipoproteinemia type III]
Tidsskr Nor Laegeforen, 113 (7), 853-6
PubMed 8480294

Leren TP, Solberg K, Rødningen OK, Ose L, Tonstad S, Berg K (1993)
Evaluation of running conditions for SSCP analysis: application of SSCP for detection of point mutations in the LDL receptor gene
PCR Methods Appl, 3 (3), 159-62
DOI 10.1101/gr.3.3.159, PubMed 8118396

Leren TP, Solberg K, Rødningen OK, Røsby O, Tonstad S, Ose L, Berg K (1993)
Screening for point mutations in exon 10 of the low density lipoprotein receptor gene by analysis of single-strand conformation polymorphisms: detection of a nonsense mutation-FH469-->Stop
Hum Genet, 92 (1), 6-10
DOI 10.1007/BF00216137, PubMed 8103503

Rødningen OK, Leren TP, Røsby O, Tonstad S, Ose L, Berg K (1993)
Haplotype analysis at the low density lipoprotein receptor locus in normal and familial hypercholesterolemia Norwegian subjects
Clin Genet, 44 (4), 214-20
DOI 10.1111/j.1399-0004.1993.tb03883.x, PubMed 7903228

SOLBERG K, RODNINGEN OK, TONSTAD S, OSE L, BERG K, LEREN TP (1993)
MSPL RFLP IN EXON 18 OF THE LDL RECEPTOR GENE DETECTABLE BY PCR
Clin. Genet., 44 (2), 111

Solberg K, Rødningen OK, Tonstad S, Ose L, Berg K, Leren TP (1993)
Short report on DNA marker at candidate locus
Clin Genet, 44 (2), 111
PubMed 8275559

Tonstad S, Ose L, Gørbitz C, Harrison EM, de Koning Gans HJ (1993)
Effectiveness of low-dose lovastatin combined with low-dose colestipol in moderate to severe primary hypercholesterolaemia
Scand J Clin Lab Invest, 53 (5), 457-63
DOI 10.1080/00365519309092540, PubMed 8210967

Publications 1992

Leren TP, Solberg K, Røsby O, Rødningen OK, Tonstad S, Ose L, Berg K (1992)
A new polymorphism in exon 11 of the LDL receptor gene in healthy people and in familial hypercholesterolemia subjects
Clin Genet, 42 (5), 224-8
DOI 10.1111/j.1399-0004.1992.tb03245.x, PubMed 1486698

Ose L (1992)
[Triglycerides, HDL and coronary disease. Consensus conference: National Institutes of Health 1992]
Tidsskr Nor Laegeforen, 112 (21), 2768-71
PubMed 1412312

Ose L (1992)
[Lovastatin in primary hypercholesterolemia. A Norwegian multicenter study]
Tidsskr Nor Laegeforen, 112 (29), 3665-9
PubMed 1471127

Pettersen AG, Eide G, Skjerdal A, Wold I, Ose L (1992)
[Quality assurance in clinical trials. Problems related to patient information]
Tidsskr Nor Laegeforen, 112 (25), 3204-7
PubMed 1462295

Purvis K, Tollefsrud A, Rui H, Haug E, Norseth J, Viksmoen L, Ose L, Lund H (1992)
Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia
Eur J Clin Pharmacol, 42 (1), 61-4
DOI 10.1007/BF00314921, PubMed 1541317

Rødningen OK, Røsby O, Tonstad S, Ose L, Berg K, Leren TP (1992)
A 9.6 kilobase deletion in the low density lipoprotein receptor gene in Norwegian familial hypercholesterolemia subjects
Clin Genet, 42 (6), 288-95
DOI 10.1111/j.1399-0004.1992.tb03258.x, PubMed 1362925

Skrede B, Blomhoff R, Maelandsmo GM, Ose L, Myklebost O, Norum KR (1992)
Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo
Eur J Clin Invest, 22 (4), 229-34
DOI 10.1111/j.1365-2362.1992.tb01456.x, PubMed 1499639

Stugaard M, Wiig I, Lund H, Ose L, Norseth J (1992)
[Familial hypercholesterolemia--intensive diet therapy combined with drug therapy]
Tidsskr Nor Laegeforen, 112 (20), 2642-6
PubMed 1412289

Publications 1991

Graff-Iversen S, Holm HA, Istad H, Ose L, Rom AK, Kristiansen IS, Thelle D, Torsvik H, Urdal P, Wiik J (1991)
[Treatment of hypercholesterolemia in adults. A treatment program 1991]
Tidsskr Nor Laegeforen, 111 (28), 3407-11
PubMed 1792668

Grønn M, Gørbitz C, Christensen E, Levorsen A, Ose L, Hagve TA, Christophersen BO (1991)
Dietary n-6 fatty acids inhibit the incorporation of dietary n-3 fatty acids in thrombocyte and serum phospholipids in humans: a controlled dietetic study
Scand J Clin Lab Invest, 51 (3), 255-63
DOI 10.3109/00365519109091612, PubMed 1909049

Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L (1991)
Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system
Arterioscler Thromb, 11 (1), 138-45
DOI 10.1161/01.atv.11.1.138, PubMed 1987991

Publications 1990

Strømme P, Ose L (1990)
[Identification of syndromes using a combined computer and video program]
Tidsskr Nor Laegeforen, 110 (9), 1085-7
PubMed 2184540

Aakhus T, Brosstad F, Halse J, Ose L, Brodwall EK, Finne P, Natvig J, Stavem P, Heiberg A, Orstavik LA (1990)
[Are prosecuted parents allowed the benefit of the doubt in cases of child abuse?]
Tidsskr Nor Laegeforen, 110 (5), 627-8
PubMed 2309218

Publications 1989

Ose L (1989)
[Marketing of Carduran]
Tidsskr Nor Laegeforen, 109 (17-18), 1920-1
PubMed 2526393

Ose L, Blomhoff JP, Torsvik H (1989)
[Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988]
Tidsskr Nor Laegeforen, 109 (7-8), 850-2
PubMed 2705170

Ose L, Grønn M, Levorsen A, Trygstad O, Lund H, Wiig I (1989)
Dietary n-3 fatty acids and children with hyperlipidaemia
J Intern Med Suppl, 731, 181-3
DOI 10.1111/j.1365-2796.1989.tb01453.x, PubMed 2706040

Ose L, Tolleshaug H (1989)
Familial hypercholesterolemia. 50 years of research
Arteriosclerosis, 9 (1 Suppl), I1-2
PubMed 2643426

Publications 1988

Silberg IE, Ose L, Flage T, Nakstad P (1988)
[Fraser's syndrome--cryptophthalmia]
Tidsskr Nor Laegeforen, 108 (25), 1998-9
PubMed 3144053

Smevik B, Enger EA, Ose L (1988)
Computed tomography of a tuberculous paravertebral abscess
Z Kinderchir, 43 (6), 430-2
DOI 10.1055/s-2008-1044106, PubMed 3239258

Publications 1987

Levorsen A, Ose L (1987)
Familiær hyperkolesterolemi: et orienteringshefte for helsepersonell og pasienter med familiær hyperkolesterolemi
Lipidklinikken, Rikshospitalet, Oslo, 15 s.
BIBSYS 932233538

Ose L (1987)
[Treatment of familial hypercholesterolemia]
Tidsskr Nor Laegeforen, 107 (32), 2836-8, 2840
PubMed 3321550

Ose L (1987)
[Cardiovascular diseases: we start with children]
Nord Med, 102 (10), 265-6
PubMed 3697042

Publications 1983

Aarskog D, Ose L, Pande H, Eide N (1983)
Autosomal dominant partial lipodystrophy associated with Rieger anomaly, short stature, and insulinopenic diabetes
Am J Med Genet, 15 (1), 29-38
DOI 10.1002/ajmg.1320150104, PubMed 6407320

Publications 1981

Berg T, Ose T, Ose L, Tolleshaug H (1981)
Intracellular degradation of 125I-labelled asialo-glycoproteins in rat hepatocytes: effect of leupeptin on subcellular distribution of asialo-fetuin
Int J Biochem, 13 (3), 253-9
DOI 10.1016/0020-711x(81)90076-8, PubMed 6163669

Ose L, Røken I, Norum KR, Drevon CA, Berg T (1981)
The binding of high density lipoproteins to isolated rat hepatocytes
Scand J Clin Lab Invest, 41 (1), 63-73
DOI 10.3109/00365518109092016, PubMed 7256194

Wandel M, Norum KR, Berg T, Ose L (1981)
Binding, uptake, and degradation of 125I-labelled high-density lipoproteins in isolated non-parenchymal rat liver cells
Scand J Gastroenterol, 16 (1), 71-80
PubMed 7233082

Publications 1980

Ose L (1980)
Studies on the lipoprotein catabolism in isolated rat liver cells
Institute for Nutrition Research, University of Oslo, Oslo, Fl. pag.
BIBSYS 812106342

Ose L, Ose T, Norum KR, Berg T (1980)
The intracellular distribution of high density lipoproteins taken up by isolated rat hepatocytes
Biochim Biophys Acta, 620 (1), 120-32
DOI 10.1016/0005-2760(80)90191-5, PubMed 6251895

Ose L, Ose T, Reinertsen R, Berg T (1980)
Fluid endocytosis in isolated rat parenchymal and non-parenchymal liver cells
Exp Cell Res, 126 (1), 109-19
DOI 10.1016/0014-4827(80)90475-9, PubMed 7188905

Ose L, Røken I, Norum KR, Berg T (1980)
The effect of ammonia, chloroquine, leupeptin, colchicine and cytochalasin B on degradation of high density lipoproteins in isolated rat hepatocytes
Exp Cell Res, 130 (1), 127-35
DOI 10.1016/0014-4827(80)90049-x, PubMed 7192635

Ose T, Berg T, Norum KR, Ose L (1980)
Catabolism of (125-I)low density lipoproteins in isolated rat liver cells
Biochem Biophys Res Commun, 97 (1), 192-9
DOI 10.1016/s0006-291x(80)80153-7, PubMed 7458932

Publications 1979

Ose L, Ose T, Norum KR, Berg T (1979)
Uptake and degradation of 125I-labelled high density lipoproteins in rat liver cells in vivo and in vitro
Biochim Biophys Acta, 574 (3), 521-36
DOI 10.1016/0005-2760(79)90248-0, PubMed 226159

Publications 1977

Levin LS, Perrin JC, Ose L, Dorst JP, Miller JD, McKusick VA (1977)
A heritable syndrome of craniosynostosis, short thin hair, dental abnormalities, and short limbs: cranioectodermal dysplasia
J Pediatr, 90 (1), 55-61
DOI 10.1016/s0022-3476(77)80764-6, PubMed 830894

Neill CA, Ose L, Kwiterovich PO (1977)
Hyperlipidemia: clinical clues in the first two decades of life
Johns Hopkins Med J, 140 (4), 171-6
PubMed 850334

Ose L (1977)
[Hyperlipemia in children]
Tidsskr Nor Laegeforen, 97 (2), 67-73
PubMed 835105

Ose L, McKusick VA (1977)
Prophylactiv use of propranolol in the Marfan syndrome to prevent aortic dissection
Birth Defects Orig Artic Ser, 13 (3C), 163-9
PubMed 19114

Publications 1976

Helle KB, Serck-Hanssen G, Sövik O, Gutteberg TJ, Hansen JR, Ose L, Stöa KF (1976)
Circulating dopamine-beta-hydroxylase (DbetaH) and catecholamines in a paediatric phaeochromocytoma
Clin Exp Pharmacol Physiol, 3 (5), 487-91
DOI 10.1111/j.1440-1681.1976.tb00627.x, PubMed 975634

Ose L, Fluge G (1976)
Letter: Usefulness of the xylose test for coeliac disease
Arch Dis Child, 51 (5), 400-1
DOI 10.1136/adc.51.5.400, PubMed 938086

Ose L, Kalager T, Grundt IK (1976)
Serum beta-lipoprotein subfractions in polyacrylamide gel electrophoresis associated with coronary heart disease
Scand J Clin Lab Invest, 36 (1), 75-9
DOI 10.1080/00365517609068021, PubMed 176718

Ragnhildstveit E, Ose L (1976)
Neonatal osteomyelitis caused by group B streptococci
Scand J Infect Dis, 8 (3), 219-21
DOI 10.3109/inf.1976.8.issue-3.20, PubMed 788147

Publications 1975

Forsdahl A, Salmi H, Forsdahl F, Ose L, Grundt I (1975)
[Finnish families in the town of Sør-Varanger. II. A study of blood pressure, height, weight, cholesterol, triglycerides and lipoprotein electrophoresis among Finnish men - combined effects of a change in diet]
Sykepleien, 62 (16), 728-35
PubMed 1043245

Ose L (1975)
Letter: L.D.L. and total cholesterol in cord-blood screening for familial hypercholesterolaemia
Lancet, 2 (7935), 615-6
DOI 10.1016/s0140-6736(75)90216-0, PubMed 51449

Ose L (1975)
[Encephalitis associated with mycoplasma pneumoniae infection in children]
Tidsskr Nor Laegeforen, 95 (12), 756-8,779
PubMed 1145545

OSE L (1975)
LDL AND TOTAL CHOLESTEROL IN CORD-BLOOD SCREENING FOR FAMILIAL HYPERCHOLESTEROLEMIA
Lancet, 2 (7935), 615-616

Ose L, Iden A, Bakke T, Aarskog D (1975)
Neonatal screening for hyperlipidaemia
Postgrad Med J, 51 (8), suppl 88-92
PubMed 215987

Ose L, Iden A, Bakke T, Aarskog D (1975)
Neonatal screening for hyperlipidaemia
Postgrad Med J, 51 (8), 88-92
PubMed 1221382

Publications 1974

Forsdahl A, Salmi H, Forsdahl F, Ose L, Grundt I (1974)
[Finnish descendants in the municipality of Sor-Varanger--II. An investigation of blood pressure, height, weight, cholesterol, triglycerides and lipoproteins among Finnish descendant men--and the effect of a diet change]
Tidsskr Nor Laegeforen, 94 (26), 1565-72
PubMed 4422489

Ose L (1974)
[Routine methods for fibrinogen determination]
Tidsskr Nor Laegeforen, 94 (30), 2085-7
PubMed 4214421

Ose L, Fluge G (1974)
[The D-xylose-tolerance test as screeningtest for malabsorption diseases in children]
Tidsskr Nor Laegeforen, 94 (18), 1192-5
PubMed 4839995

Publications 1973

Ose L (1973)
[D-xylose tolerance in malabsorption. Method of determination of D-xylose in serum and urine]
Tidsskr Nor Laegeforen, 93 (28), 2103-5
PubMed 4773981